Quick Answer
Lyra Therapeutics, Inc. reported Diluted EPS of $18.62 per share (loss) for fiscal year 2025.
Lyra Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$18.62 | +74.0% |
| 2024 | -$71.75 | -5594.4% |
| 2023 | -$1.26 | +31.1% |
| 2022 | -$1.83 | +45.4% |
| 2021 | -$3.35 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.38 | +62.7% | +38.7% |
| June 30, 2025 | -$5.51 | +85.0% | -4138.5% |
| March 31, 2025 | -$0.13 | +62.9% | +98.6% |
| September 30, 2024 | -$9.07 | -3259.3% | +75.3% |
| June 30, 2024 | -$36.76 | -10111.1% | -10402.9% |
| March 31, 2024 | -$0.35 | +20.5% | -29.6% |
| September 30, 2023 | -$0.27 | +32.5% | +25.0% |
| June 30, 2023 | -$0.36 | +14.3% | +18.2% |
- Lyra Therapeutics, Inc. showed an increase of +74.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Lyra Therapeutics, Inc.’s diluted eps has declined by 455.8% (from $3.35 per share (loss) to $18.62 per share (loss)).
- The most recent figure is from Lyra Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: